Testing a new inhaled medication for chronic lung obstruction

Plain-English translation of NCT07140328 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a new inhaled medication called HSK39004 to see if it can help treat chronic obstructive pulmonary disease (COPD), a serious lung condition that makes breathing difficult. Researchers want to compare the medication in two different forms (a dry powder and a liquid suspension) at different doses against a placebo to determine which works best and is safest for patients.

COPD is a long-term lung disease that causes progressive breathing problems, and patients need better treatment options. This medication may help reduce symptoms and improve lung function in people with COPD.

Do you qualify?

You likely qualify if…

you are between 40 and 80 years old
you have been diagnosed with COPD according to current medical standards and have had symptoms for at least one year
your lung function tests show a specific pattern consistent with COPD
your COPD has been stable for at least 4 weeks before joining the trial
you have a significant smoking history (at least 10 pack-years) or exposure to other lung disease risk factors

You likely don't qualify if…

you have had a COPD flare-up requiring hospitalization or treatment within the past 12 weeks
you have had a respiratory infection requiring antibiotics within the past 6 weeks
you have other serious lung diseases such as asthma, tuberculosis, cystic fibrosis, or pulmonary fibrosis
you have severe heart disease or have had a heart attack, unstable chest pain, or serious irregular heartbeat in the past 6 months

What participation looks like

You would visit the research clinic for screening and then be randomly assigned to take either the new medication or a placebo, both inhaled through your mouth twice a day. Some participants will receive the medication as a dry powder, while others receive it as a liquid suspension, at different strengths. You'll have follow-up visits to check how well the treatment works and monitor for any side effects.

AI-generated summary from trial data · Jun 26, 2026 · Not medical advice

Trial locations(1 site)

China

Jiangsu Provincial People's Hospital, Nanchang, Jiangsu